CTLA4 and metastatic neoplasm: Checkpoint blockade with PD-1 and CTLA-4 showed durable control of highly aggressive melanomas and has led to spectacular results showing rapid eradication of large metastatic tumors in response to one dose of Ipilimumab (CTLA-4) and Nivolumab (PD-1) (1, 2).